Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
PRODIGE 24
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
- NCT01526135 ↗
- Completed
- UNICANCER
- Deep
We haven't built an HCP commentary report on PRODIGE 24 (mFOLFIRINOX in resected pancreatic adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PRODIGE 24 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 65 | |
| YouTube | 5 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
- Interventions
- mFolfirinox; Gemcitabine
- Arms
- Arm A GEMCITABINE · Active comparator
- Arm B mFOLFIRINOX · Experimental
- Enrollment
- 493
- Primary outcomes
- disease-free survival (DFS)
- Sponsor
- UNICANCER with Canadian Cancer Trials Group
- Start
- Apr 16, 2012
- Primary completion
- Mar 2018
- Results posted
- No
- Registry record
- NCT01526135 · updated Jan 4, 2022
Publications
linked from the registry- Witz A, Conroy T, Lambert A, Salleron J, Diallo A, Husson M, Nicolle R, Hammel P, Biagi J, Renouf DJ, Turpin A, Richard C, Bachet JB, Iovanna J, Dusetti N, Monard L, Mauduit M, Cros J, Harle A. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. J Clin Oncol. 2026 Sep 10;44(26):2517-2528. doi: 10.1200/JCO-25-02508. Epub 2026 Aug 3. PubMed 42546248
- Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouche O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. PubMed 36048453
- Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. PubMed 30575490